Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E23.15 EPS (ttm)1.86 Insider Own0.06% Shs Outstand5.88B Perf Week2.36%
Market Cap252.39B Forward P/E14.07 EPS next Y3.05 Insider Trans-1.21% Shs Float5.80B Perf Month1.90%
Income11.14B PEG3.88 EPS next Q0.75 Inst Own73.10% Short Float0.74% Perf Quarter-2.76%
Sales53.65B P/S4.70 EPS this Y68.20% Inst Trans-1.45% Short Ratio1.62 Perf Half Y1.90%
Book/sh12.14 P/B3.54 EPS next Y5.86% ROA13.50% Target Price44.46 Perf Year20.13%
Cash/sh2.93 P/C14.64 EPS next 5Y5.96% ROE31.90% 52W Range34.32 - 46.47 Perf YTD-1.58%
Dividend1.44 P/FCF32.88 EPS past 5Y10.40% ROI11.00% 52W High-7.55% Beta0.74
Dividend %3.35% Quick Ratio1.20 Sales past 5Y-0.80% Gross Margin79.30% 52W Low25.17% ATR0.78
Employees90200 Current Ratio1.40 Sales Q/Q1.00% Oper. Margin25.20% RSI (14)57.18 Volatility1.47% 1.93%
OptionableYes Debt/Eq0.58 EPS Q/Q45.80% Profit Margin42.00% Rel Volume0.89 Prev Close42.14
ShortableYes LT Debt/Eq0.47 EarningsJan 29 BMO Payout34.80% Avg Volume26.35M Price42.96
Recom2.50 SMA202.75% SMA501.28% SMA2004.87% Volume23,453,530 Change1.95%
Feb-20-19Resumed Citigroup Neutral $41
Jan-31-19Upgrade Credit Suisse Neutral → Outperform
Jan-31-19Upgrade Argus Hold → Buy
Jan-23-19Downgrade UBS Buy → Neutral
Dec-11-18Downgrade JP Morgan Overweight → Neutral
Nov-01-18Downgrade BMO Capital Markets Outperform → Market Perform
Jun-08-18Initiated Cantor Fitzgerald Overweight $45
Apr-05-18Downgrade Barclays Overweight → Equal Weight $41 → $38
Jan-29-18Reiterated SunTrust Hold $33 → $40
Sep-20-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-17Downgrade Credit Suisse Outperform → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Feb-23-19 12:04PM  The Dogs of the Dow Start 2019 Slow Motley Fool
Feb-22-19 06:05PM  Trump nominates Kelly Craft as UN ambassador CNBC
01:27PM  Intel, Pfizer Lead Dow Jones Rally; 3 Stocks Explode Higher On Earnings Investor's Business Daily
01:01PM  U.S. closes IV solution shortage antitrust probe, Baxter says Reuters
10:47AM  Pfizer executive Sally Susman to host 2020 presidential fundraiser for Democrat Kirsten Gillibrand CNBC
09:04AM  Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates Zacks
07:41AM  Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review Zacks
12:52AM  Icon PLC (ICLR) Q4 2018 Earnings Conference Call Transcript Motley Fool
12:49AM  EXACT Sciences Corporation (EXAS) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-21-19 09:39PM  What Pharma Investors Need to Know About Pfizer's Latest Disaster Motley Fool
08:33AM  Fears of Amazon appear overblown as companies that fretted competition went on to beat market CNBC
Feb-20-19 04:48PM  Market Recap for Wednesday February 20 Yahoo Finance Video
04:26PM  Better Buy: Pfizer vs. Eli Lilly Motley Fool
08:42AM  Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study Zacks
Feb-19-19 05:17PM  Spark Therapeutics (ONCE) Q4 2018 Earnings Conference Call Transcript Motley Fool
10:30AM  Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials Business Wire
10:07AM  What's in Store for Sangamo (SGMO) This Earnings Season? Zacks
09:32AM  Pfizer Receives European Approval for ZIRABEV (bevacizumab), a Biosimilar to Avastin®* Business Wire
08:30AM  Gliknik To Receive $15 Million Milestone Payment From Pfizer Inc. Following Clinical Progress With PF-06755347, Previously Known As GL-2045 PR Newswire
07:22AM  Pfizer-Lilly drug shown to help reduce back pain in late-stage trial Reuters
07:17AM  Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster Motley Fool
06:56AM  Higher dose of Pfizer-Lilly drug helps reduce back pain in study Reuters
06:45AM  Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain PR Newswire
Feb-18-19 08:10AM  Merck Gets Priority Review for Keytruda Combo in Kidney Cancer Zacks
06:00AM  Big Pharma Cant Resist Big Mergers. Heres Why. Barrons.com
Feb-16-19 05:10PM  Merck, Pfizer drug combo extends kidney cancer survival -study Reuters
Feb-15-19 04:18PM  Pharmacia Corporation (Old Monsanto) -- Moody's announces completion of a periodic review of ratings of Pfizer Inc. Moody's
01:21PM  This Is One Company That Could Break Up Bristol-Celgene Deal Investor's Business Daily
08:56AM  Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review Zacks
Feb-14-19 04:45PM  Bayer stresses drug's tolerability in bid for prostate cancer market Reuters
07:50AM  The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial Benzinga
05:00AM  Pfizer still holds the lead in the erectile dysfunction market even as Viagra sales falter CNBC
Feb-13-19 03:36PM  Conatus (CNAT) Completes Enrollment in Phase II NASH Study Zacks
01:25PM  Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4 Zacks
05:00AM  Dogs of the Dow and a 3 Top Dogs Strategy MoneyShow
Feb-12-19 05:57PM  Bristol-Myers' Sprycel Gets European Nod for Label Expansion Zacks
10:10AM  Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review Zacks
09:38AM  Stock Market News For Feb 12, 2019 Zacks
07:17AM  Better Buy: Gilead Sciences vs. Pfizer Motley Fool
Feb-11-19 08:01PM  Merck, Pfizer combo treatment boosts kidney cancer survival Reuters
05:44PM  FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma PR Newswire
05:00PM  Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer PR Newswire
04:07PM  Stocks Start Week of Trade Talks on Muted Note: Markets Wrap Bloomberg
12:07PM  Stocks making the biggest moves midday: Avis Budget Group, Pfizer, Tesla & more CNBC
09:31AM  Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake Zacks
Feb-10-19 05:37PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Feb-08-19 04:14PM  This Gene Therapy Stock Could Soon Hit The Auction Block Here's Why Investor's Business Daily
09:53AM  Pfizer Japan recalls high blood pressure drug over cancer-causing impurity Reuters
09:41AM  Pfizer Japan recalls high blood pressure drug over cancer-causing impurity Reuters
07:51AM  Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs Zacks
07:29AM  Dow 30 Stock Roundup: Disney Earnings Impress, Pfizer's Cancer Drug Gets CHMP Nod Zacks
07:20AM  Pfizer Japan recalls high blood pressure drug Amvalo due to carcinogen Reuters
05:00AM  Buying the Dow Stocks With the Highest Dividends Is a Winning Strategy Barrons.com
Feb-07-19 09:00AM  Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19 Zacks
Feb-06-19 05:52PM  At least four pharma CEOs to testify at Senate drug pricing hearing Reuters
01:48PM  Eli Lilly Stock Falls Because 2019 Isnt 2018 Barrons.com
01:37PM  At least four pharma CEOs to testify at Senate drug pricing hearing Reuters
12:16PM  Congress invites 7 drugmakers to testify at potentially hostile hearing on drug prices. Here's what they're saying CNBC
09:44AM  Pfizer CEO Bourla plans to testify at Senate drug pricing hearing Reuters
07:48AM  Cancer-Vaccine Maker BioNTech Considering an IPO in U.S. Bloomberg
06:08AM  Winners & Losers from Trump's State of the Union Address Zacks
Feb-05-19 04:06PM  Merck CEO Frazier to testify at Senate drug pricing hearing Reuters
11:38AM  Pharma execs will testify before Congress 'one way or another,' US senator says CNBC
08:07AM  Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies Zacks
08:03AM  Corporate Profits' New Enemy Is the 'Dollar Vortex' Investopedia
Feb-04-19 09:47PM  Here's Why Exact Sciences Soared 42.8% in January Motley Fool
08:48AM  Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod Zacks
08:05AM  The Zacks Analyst Blog Highlights: Boeing, Thermo Fisher, Anthem, PayPal and Pfizer Zacks
Feb-03-19 09:16AM  Pfizer's Next 3 Years: What Investors Can Expect Motley Fool
09:01AM  A War on High Drug Prices Could Boost Biosimilars Motley Fool
Feb-02-19 02:17PM  Pricing Pressure a Hard Pill for Pharma to Swallow Barrons.com
Feb-01-19 08:01PM  It's Official: Trump Proposes Plan to Stop Skyrocketing Drug Prices Motley Fool
02:24PM  Top Analyst Reports for Boeing, Thermo Fisher & Anthem Zacks
10:15AM  Pharma Catches Another Case Of M&A Fever Benzinga
09:17AM  Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations Business Wire
08:27AM  Dow 30 Stock Roundup: MCD, BA, 3M, MSFT, PFE, V Earnings Impress Zacks
08:15AM  Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY Zacks
Jan-31-19 12:06PM  Merck's Pneumococcal Vaccine Gets Breakthrough Therapy Status Zacks
11:27AM  Pfizer Stocks Dark Period Might Finally Be Over Barrons.com
09:50AM  Pfizer Rises 3% Investing.com
Jan-30-19 11:45PM  Why are deep-pocketed biotechs cutting hundreds of jobs? American City Business Journals
07:01PM  Jim Cramer: When Is a Miss Not a Miss? TheStreet.com
04:34PM  Edited Transcript of PFE earnings conference call or presentation 29-Jan-19 3:00pm GMT Thomson Reuters StreetEvents
02:47PM  What Should Apple Do With Its Cash? InvestorPlace
12:46PM  Pfizer's Near-Term Correction Could Be Over TheStreet.com
11:03AM  Pfizer Beats Expectations but Reaction Is Muted GuruFocus.com
09:30AM  Company News For Jan 30, 2019 Zacks
08:52AM  Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study Zacks
08:46AM  Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid Zacks
08:16AM  3 Big Pharmas Expecting a Softer 2019 Motley Fool
07:28AM  A Cure for Cancer Next Year? The Stock Market Says Don't Believe the Hype Motley Fool
07:00AM  New Jerseys College Savings Plan Bought Up AT&T, Amazon, and GM Stock Barrons.com
12:40AM  Pfizer Well-Positioned, Undervalued Morningstar
Jan-29-19 10:14PM  Pfizer (PFE) Q4 2018 Earnings Conference Call Transcript Motley Fool
09:34PM  Better Buy: Johnson & Johnson vs. Pfizer Motley Fool
08:17PM  [$$] Pfizer Results Hurt by Pricing Challenges The Wall Street Journal
06:41PM  Here's when an earnings miss isn't really a miss: Jim Cramer CNBC
05:20PM  US Market Indexes Close Flat on Tuesday GuruFocus.com
05:12PM  What Happened in the Stock Market Today Motley Fool
04:57PM  3 Stocks Move Tuesday GuruFocus.com
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; Immunicum AB (publ); Immutep Limited; BioNTech AG; Neofluidics, LLC; Kite Pharma, Inc.; Leap Therapeutics, Inc.; Nektar Therapeutics; Zenith Epigenetics Ltd., and Kineta Immuno-Oncology, LLC, as well as development agreement with Antares Pharma, Inc. It also has a collaboration agreement with Aileron Therapeutics, Inc. The company was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LANKLER DOUGLAS MExecutive Vice PresidentFeb 01Sale42.755,000213,75040,057Feb 01 07:21 PM
Dolsten MikaelPresident R&DJan 31Option Exercise29.78125,9683,751,425362,051Feb 01 07:28 PM
LANKLER DOUGLAS MExecutive Vice PresidentJan 30Sale41.1938,8001,598,07145,057Feb 01 07:21 PM
READ IAN CChairman & CEONov 02Option Exercise26.641,100,20129,312,5881,760,958Nov 06 03:46 PM
PFIZER INC10% OwnerOct 15Buy18.0055,5561,000,00822,032,040Oct 17 05:17 PM
Dolsten MikaelPresident R&DSep 13Option Exercise24.56181,7124,462,167234,299Sep 17 04:08 PM
OLSON LAURIE JExecutive Vice PresidentAug 13Sale41.0010,214418,77472,672Aug 14 05:04 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentAug 03Sale39.5125,6421,013,171102,412Aug 06 03:19 PM
GOETTLER MICHAELGroup PresidentAug 01Sale39.7019,198762,11611,924Aug 03 03:38 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerAug 01Sale40.1626,8141,076,93383,846Aug 03 03:36 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentAug 01Sale40.0420,942838,5724,643Aug 03 03:35 PM
DAMELIO FRANK AExecutive Vice PresidentAug 01Sale40.00150,4846,019,360337,391Aug 03 03:33 PM
SUSMAN SALLYExecutive Vice PresidentJul 20Sale37.2240,3811,502,925115,096Jul 24 01:09 PM
READ IAN CChairman & CEOJul 16Sale37.36486,75318,186,315659,440Jul 17 04:59 PM
OLSON LAURIE JExecutive Vice PresidentJun 06Sale36.4519,000692,58282,886Jun 08 01:11 PM
CORNWELL W DONDirectorJun 04Sale36.405,223190,1170Jun 05 04:44 PM
READ IAN CChairman & CEOMay 01Sale36.01132,3124,764,0811,144,703May 03 04:19 PM
JOHNSON RADY AExecutive Vice PresidentMar 13Sale36.5527,323998,66643,178Mar 14 05:19 PM
LANKLER DOUGLAS MExecutive Vice PresidentMar 13Sale36.8950,0001,844,39883,857Mar 14 05:13 PM
Dolsten MikaelPresident R&DMar 09Sale36.5969,6992,550,39451,185Mar 12 05:01 PM
HILL CHARLES HExecutive Vice PresidentMar 06Sale35.7642,3931,515,98557,328Mar 07 04:09 PM
Dolsten MikaelPresident R&DMar 02Sale35.8513,986501,398120,884Mar 05 09:23 AM
HILL CHARLES HExecutive Vice PresidentFeb 28Option Exercise27.37101,8722,788,237207,942Mar 02 03:24 PM
YOUNG JOHN DGroup PresidentFeb 28Option Exercise27.37121,1453,315,739362,707Mar 02 04:10 PM
OLSON LAURIE JExecutive Vice PresidentFeb 28Option Exercise27.3738,5461,055,004132,702Mar 02 04:02 PM
READ IAN CChairman & CEOFeb 28Option Exercise27.37649,78017,784,4791,774,184Mar 02 04:03 PM
SUSMAN SALLYExecutive Vice PresidentFeb 28Option Exercise27.37110,1323,014,313245,362Mar 02 04:03 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50239,801Mar 02 03:44 PM
JOHNSON RADY AExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50285,910Mar 02 03:44 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 28Option Exercise27.3746,8061,281,080171,276Mar 02 03:44 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 28Option Exercise27.37104,6262,863,614384,219Mar 02 03:44 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 28Option Exercise27.37209,2515,727,200655,161Mar 02 03:24 PM
BOURLA ALBERTChief Operating OfficerFeb 28Option Exercise27.3739,9231,092,693184,120Mar 02 03:24 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 28Option Exercise27.3733,040904,305136,847Mar 02 03:24 PM
Dolsten MikaelPresident R&DFeb 28Option Exercise27.37198,2385,425,774293,352Mar 02 03:24 PM
HILL CHARLES HExecutive Vice PresidentFeb 28Sale36.8326,779986,292181,163Mar 02 03:24 PM
SUSMAN SALLYExecutive Vice PresidentFeb 27Sale37.0333,3681,235,591135,230Feb 28 06:14 PM
Dolsten MikaelPresident R&DFeb 27Sale37.0464,5872,392,31395,114Feb 28 06:04 PM
CORNWELL W DONDirectorFeb 27Sale37.0530011,1150Feb 28 01:29 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 26Sale37.199,510353,67717,770Feb 27 07:38 PM
CORNWELL W DONDirectorFeb 26Sale36.741,45853,5640Feb 28 01:29 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9043,520822,528223,733Feb 27 08:59 PM
READ IAN CChairman & CEOFeb 24Option Exercise19.83903,55917,917,2651,560,007Feb 27 08:58 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9015,716297,03290,222Feb 27 07:53 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456206,972Feb 27 07:51 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9015,885300,22762,848Feb 27 07:43 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9028,288534,643112,081Feb 27 07:43 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456313,499Feb 27 07:43 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 24Option Exercise18.9015,957301,58736,959Feb 27 07:38 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentFeb 24Option Exercise18.9039,555747,590143,152Feb 27 07:38 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9065,2801,233,792122,609Feb 27 07:38 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90174,0813,290,131225,265Feb 27 07:32 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9028,288534,643116,769Feb 27 07:30 PM
BOURLA ALBERTChief Operating OfficerFeb 24Option Exercise18.9025,387479,814158,170Feb 27 07:30 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90174,0813,290,131511,470Feb 27 07:30 PM